Stifel maintains Alcon stock Buy rating, $100 price target

Tuesday, Stifel analysts upheld their Buy rating and $100.00 price target for Alcon Inc. (NYSE:ALC), a leader in eye care products currently trading at $92.35 with a market capitalization of $45.8 billion. According to InvestingPro analysis, the stock appears overvalued at current levels, though it maintains strong financial health metrics. Stifel anticipates the company’s forthcoming Capital Markets Day (CMD) to provide an in-depth look at Alcon’s growth and value drivers, particularly highlighting its strong product cycle, which is expected to begin with the launches of UNITY and PanOptix Pro in the second quarter of 2025.

The analysts believe Alcon’s product releases will play a significant role in the medical technology sector, with the company’s defensive market position — characterized by minimal exposure to consumer demand fluctuations, tariffs, and GLP-1 risks — contributing to its reputation as a stable investment amidst market volatility. InvestingPro data supports this view, showing the stock’s low volatility with a beta of 0.83 and strong financial health score of 3.11. The company’s solid balance sheet, with current ratio of 2.77, and moderate debt levels further reinforce its position as a recommended fundamental long-term holding.

Despite the positive outlook, Stifel analysts expressed some reservations about the potential for Alcon’s stock to surpass its second-half-weighted and new product-dependent guidance for 2025. The CMD’s impact on the stock price in the near term is also uncertain. The analysts speculate that a high single-digit percentage implied compound annual growth rate (CAGR) for 2025-2029 sales, potentially reaching $14 billion by 2029, would underscore management’s confidence in Alcon’s product cycle narrative. Current revenue stands at $9.91 billion with a growth rate of 4.82%. For deeper insights into Alcon’s growth potential and comprehensive financial analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 top US stocks.

Alcon’s CMD is expected to be a pivotal event, offering investors and analysts alike a comprehensive overview of the company’s strategic initiatives and product pipeline. The event will likely address the anticipated impact of new product introductions on the company’s financial performance and market position in the coming years.

The firm’s commentary suggests that while there is confidence in Alcon’s long-term prospects, there is a degree of caution regarding the immediate future, given the dependency on new product launches and the company’s guidance for the latter half of the year. Alcon’s stock performance following the CMD will be closely watched by investors seeking to gauge the company’s trajectory and the market’s response to its strategic plans.

In other recent news, Alcon Inc. has been the focus of several analyst updates and strategic developments. BofA Securities upgraded Alcon’s stock rating from Neutral to Buy, with a new price target of CHF96.00, citing an anticipated earnings upgrade cycle driven by upcoming product launches. The firm projects a 9% increase in constant currency sales and a 2.5 percentage point margin improvement by the fourth quarter of 2025. Stifel maintained its Buy rating and $100.00 price target, emphasizing Alcon’s defensive market position and potential growth from its product cycle, though it noted some uncertainty regarding the company’s second-half guidance for 2025. Needham also reiterated a Buy rating with a $107.00 target, highlighting the significance of Alcon’s upcoming Capital Markets Day as a pivotal event for strategic insights and financial updates. Additionally, Bernstein reinstated coverage with an Outperform rating and a price target of CHF97.50, pointing to Alcon’s strong market presence and commitment to research and development. The company is set to launch seven new products in the U.S. in 2025, including a new phacoemulsification machine and an advanced intraocular lens, which are expected to enhance its competitive position. These developments reflect Alcon’s strategic focus on innovation and market expansion in the ophthalmology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.